Six top tips to prepare for the new EU Clinical Trial Regulation

The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.


Open PDF

Return to Insights Center

Related Insights

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Blog

New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure

Jan 13, 2023

Playbook

Are you using real-world evidence?

Feb 1, 2023

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Article

Relyvrio Approval: Lessons Learned

Oct 31, 2022

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Related Insights

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Show more